Malin Corporation | MLC - Cash And Equivalent


Malin Corporation reported EUR62.1M in Cash and Equivalent for its fiscal semester ending in December of 2024.





Cash And Equivalent Change Date
Akebia Therapeutics USD 166.44M 29.14M Sep/2025
Alaunos Therapeutics USD 1.94M 941K Sep/2025
ALKERMES USD 616.45M 95.25M Sep/2025
Avita Medical AUD 12.22M 1.83M Jun/2025
Dianthus Therapeutics USD 55.98M 42.75M Sep/2025
Eurofins Scientific SE EUR 753.3M 139.4M Jun/2025
Ionis Pharmaceuticals USD 2.24B 1.94B Sep/2025
IQVIA Holdings USD 1.98B 166M Dec/2025
Lonza CHF 1.11B 286M Dec/2024
Malin Corporation EUR 62.1M 26.4M Dec/2024
Moderna USD 2.6B 1.46B Dec/2025
Organon & Co USD 672M 73M Sep/2025
Revvity USD 919.86M 11.53M Dec/2025
Tectonic Therapeutic USD 268.44M 18.94M Sep/2025
Viatris USD 975.3M 408.9M Sep/2025
Xeris Pharmaceuticals USD 91.6M 32.32M Sep/2025